Full-Time

Process Development Associate Director

Commercial Packaging Equipment

Posted on 6/15/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$168.9k - $197.5k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

New Albany, OH, USA

Category
Process Engineering
Requirements
  • Doctorate degree & 3 years of Engineering experience
  • OR Master’s degree & 5 years of Engineering experience
  • OR Bachelor’s degree & 7 years of Engineering experience
  • OR Associate’s degree & 12 years of Engineering experience
  • OR High school diploma / GED & 14 years of Engineering experience.
Responsibilities
  • Leading the New Product Introduction (NPI) process
  • Equipment Characterization and Validation for all GMP equipment and processes at the AOH site
  • Provision of technical operations support for the continuous improvement of packaging lines capacity and performance
  • Advisory of technical improvement projects
  • Ensure effective communication throughout the Amgen commercial site network with all partners
  • Support the delivery of productivity, throughput and general capacity improvements across the AOH site by analyzing, designing, and implementing manufacturing and business process improvements
  • Manage new process equipment and technology
  • Lead the Commissioning, Qualification and Validation of all process and GMP equipment located at AOH
  • Own the site master validation plan for GMP equipment and be responsible for the maintenance and execution of this
Desired Qualifications
  • Excellent written and verbal communication skills together with demonstrated ability to work in a team environment.
  • Proven track record of leading and executing cross-functional projects.
  • Strong teamwork, excellent interpersonal and communication skills.
  • Direct experience with the manufacturing process for combination products, assembly, label & packaging operations.
  • Experience of working with Final Drug Product equipment suppliers.
  • Ability to work in a highly regulated and ever changing industry.
  • Ability to learn and rapidly adapt to new requirements in a fast moving environment.
  • An Operational Excellence approach to work product – driving rapid results.
  • A passion to deliver an excellent work product and develop others with an infective positive attitude!

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.